SAB4200794

Anti-Involucrin antibody, Mouse monoclonal

clone SY5, purified from hybridoma cell culture

• Synonym(s): Anti-IVL
• UNSPSC Code: 12352203
• NACRES: NA.41

Properties

• biological source: mouse
• Quality Level: 200
• antibody form: purified from hybridoma cell culture
• antibody product type: primary antibodies
• clone: SY5, monoclonal
• form: buffered aqueous solution
• mol wt: ~68 kDa
• species reactivity: canine, gorilla, porcine, mouse, human, owl monkey
• concentration: ~1 mg/mL
• technique(s): immunoblotting: suitable; immunofluorescence: suitable; immunohistochemistry: 2.5-5 μg/mL using human skin sections; immunoprecipitation (IP): suitable
• isotype: IgG1
• UniProt accession no.: P07476
• shipped in: dry ice
• storage temp.: −20°C
• target post-translational modification: unmodified
• Gene Information: human ... IVL(3713)

Description

General description

Monoclonal Anti-Involucrin (mouse IgG1 isotype) is derived from the SY5 hybridoma, produced by the fusion of mouse myeloma cells and splenocytes from a mouse immunized with purified human involucrin. Involucrin is a soluble cytoplasmic protein. It is expressed in a range of stratified squamous epithelia, including the cornea, which lacks a distinct cornified layer.

The skin serves as a vital barrier that protects the internal environment from external influences. As cells start to migrate out of the basal cell layer of the epidermis towards the surface of the skin, it lose the ability to divide and progress towards a terminal differentiation stage. During this process, keratinocytes go through marked morphological and structural changes. At the same time, the synthesis of important differentiation-dependent structural and catalytic proteins is initiated, which include keratins, filaggrin, transglutaminase, loricrin and involucrin. Involucrin (IVL) is a soluble cytoplasmic protein precursor of the epidermal cornified envelope that becomes crosslinked by transglutaminase during envelope assembly. Involucrin is expressed in a range of stratified squamous epithelia, including the cornea, which lacks a distinct cornified layer. It serves as an early marker of keratinocyte differentiation and a component of the cornified envelope. It is specifically expressed in the suprabasal layers of the epidermis. Involucrin accumulates in the spinous and granular layers as a non-crosslinked precursor and becomes covalently crosslinked to other proteins and lipids to form the cornified envelope scaffolding during the final stages of keratinocyte differentiation. Cell that have lost their ability to divide still continue to express Involucrin.

In pathological conditions, involucrin expression may be altered. In psoriasis and other benign epidermal hyperplasias, involucrin expression appears closer to the basal layer than it′s normal expression. In squamous cell carcinomas and premalignant lesions, involucrin is abnormally increases and found to be reduced in severe dysplasias of the larynx and cervix.

Monoclonal Anti-Involucrin specifically recognizes human and mouse Involucrin. The antibody does not react with mouse epidermis, thus enabling the use of the antibody for study of human xenografts in nude mice. The antibody stains the upper spinous and granular layers in human skin and the cytoplasm of suprabasal terminally differentiated keratinocytes in stratified colonies.

Immunogen

purified human involucrin

Application

Anti-Involucrin antibody, Mouse monoclonal is recommended to use in various immunological techniques, including:

• Immunoblot
• Immunofluorescence
• Immunohistochemistry
• Immunoprecipitation

Biochem/physiol Actions

Involucrin (IVL) acts as a precursor of the epidermal cornified envelope that becomes crosslinked by transglutaminase during envelope assembly. Involucrin accumulates in the spinous and granular layers as a non-crosslinked precursor and becomes covalently crosslinked to other proteins and lipids to form the cornified envelope scaffolding during the final stages of keratinocyte differentiation. Cells that have lost their ability to divide express involucrin. In pathological conditions, involucrin expression may be altered. In psoriasis and other benign epidermal hyperplasias, involucrin expression appears closer to the basal layer than its normal expression. In squamous cell carcinomas and premalignant lesions, involucrin is abnormally increased and found to be reduced in severe dysplasias of the larynx and cervix.

Physical form

Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Other Notes

This product is for R&D use only, not for drug, household, or other uses.

Safety Information

• Storage Class Code: 12 - Non Combustible Liquids
• WGK: WGK 1